Handok, Mitsubishi Tanabe announces licensing agreement for novel DPP-4 agent
Published: 2012-02-02 06:59:00
Updated: 2012-02-02 06:59:00
Handok Pharma and Mitsubishi Tanabe Pharma announced Tuesday the execution of a license agreement granting Hanmi to market Mitsubishi Tanabe’s new dipeptidyl peptidase 4 (DPP-4 agent) MP-513 (teneligliptin) for the treatment of type 2 diabetes.
Under the agreement, Handok will carry out clinic...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
